Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that target a critical pathway and various central targets in DNA damage response and cancer progression. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that target a critical pathway and various central targets in DNA damage response and cancer progression. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.